Abstract
Early detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been proven crucial during the efforts to mitigate the effects of the COVID-19 pandemic. Several diagnostic methods have emerged in the past few months, each with different shortcomings and limitations. The current gold standard, RT-qPCR using fluorescent probes, relies on demanding equipment requirements plus the high costs of the probes and specific reaction mixes. To broaden the possibilities of reagents and thermocyclers that could be allocated towards this task, we have optimized an alternative strategy for RT-qPCR diagnosis. This is based on a widely used DNA-intercalating dye and can be implemented with several different qPCR reagents and instruments. Remarkably, the proposed qPCR method performs similarly to the broadly used TaqMan-based detection, in terms of specificity and sensitivity, thus representing a reliable tool. We think that, through enabling the use of vast range of thermocycler models and laboratory facilities for SARS-CoV-2 diagnosis, the alternative proposed here can increase dramatically the testing capability, especially in countries with limited access to costly technology and reagents.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT, grant IP-COVID-19 429 to ARK) and by Fondos del Presupuesto del Servicio de Virosis Respiratorias, INEI-ANLIS Malbran (MA, AP, EB and EB). FFW is an ANPCYT fellow; MAGH, JCM, JNS, LB, NNM, MP, LS and GC are fellows from Consejo Nacional de Investigaciones Cientificas y Tecnicas de Argentina (CONICET); JC and VB are support staff for research and development (CPA) from CONICET; FRL, CCG, ARK, AS, MdlM, MJM, IES and EP are career investigators from CONICET.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used the remaining volume of anonymized samples that had been collected for clinical diagnosis. Under these circumstances, and for studies involving development of COVID-19 diagnostic tools, our IRB (the Research Ethics Committee from Fundacion Huesped in Buenos Aires, Argentina) deemed unnecessary to obtain informed consent from the patients and waived the ethical approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is part of the main figures or the suppl. information. If there is any other data a reader may need or further info on methods, do not hesitate to contact the authors.
